Sanaria’s Chief Executive and Scientific Officer, Dr. Hoffman, recognized as one of Ten International Vaccine Influencers Who Exemplify Maryland’s Leading Role in Public Health in BioBuzz

Dr. Stephen Hoffman, Sanaria’s Chief Executive and Scientific Officer was recognized by BioBuzz as one of ten international vaccine influencers who exemplify Maryland’s leading role in public health.

Dr. Hoffman was recognized by BioBuzz for both his current work and his past accomplishments. Dr. Hoffman has led Sanaria since 2003 to develop a malaria vaccine and has been a global leader in the malaria field for many years prior. Previously, he was the malaria program director at the Naval Medical Research Center from 1987-2001. During this time, his team was developing subunit malaria vaccines, sequencing the Plasmodium falciparum genome, and published the first ever studies showing DNA vaccines elicited killer T cells in humans. Dr. Hoffman contributed greatly to the knowledge of malaria and is the most highly cited author (globally) for scientific papers on malaria published between 1995 and 2005.

Since starting Sanaria, Dr. Hoffman and his team has developed the PfSPZ platform technology that has lead to several malaria vaccine candidates that are safe, well-tolerated, and elicit protection against malaria. In recent years, Dr. Hoffman was listed as the third most influential person in the world vaccine industry when he received the Vaccine Industry Excellence Award for Best Biotech CEO in 2015. Additionally this year under his leadership, Sanaria received both the P3 Impact Award from Concordia which recognizes leading Public-Private-Partnerships that improve communities and the world for the Bioko Island Malaria Elimination Project as well as the Patents for Humanity Award given by the United States Patent and Trademark Office for developing a whole parasite vaccine for malaria. The Patents for Humanity award is judged on the effectiveness of the patented technology to address humanitarian issues, contributions to use the technology among the impoverished, and the impact those contributions had made to improve lives.

Sanaria is also working on multiple projects related to developing a vaccine against COVID-19. The flagship vaccine is called Oracov, which is a orally-administered COVID-19 vaccine being developed by Sanaria along with Protein Potential, LLC., and the University of Tübingen.

The full article can be found on BioBuzz by visiting this link or by visiting Biobuzz.io.